CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00459342
NCT00459342Phase 2Completed
CompareCT.gov

Phase II Study of Dasatinib in Non Small Cell Lung Cancer

National Cancer Institute (NCI)·interventional·Posted Apr 11, 2007·Updated Mar 5, 2019

In Brief

A Phase 2 clinical trial evaluating dasatinib for Non-small Cell Lung Cancer and 3 related conditions. Completed, enrolled 35 participants across 1 site.

Detailed Summary

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 11, 2007
Enrollment StartMar 1, 2007
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 19.2 years ago

Interventions

dasatinibdrug

Given orally